Logo

American Heart Association

  1
  0


Final ID: WP135

Race-Ethnic Specific Hospital Arrival Time of Acute Ischemic Stroke by State in the U.S.

Abstract Body: Introduction
Arriving at the hospital after 4.5 hours of stroke onset makes a patient ineligible for intravenous thrombolytic therapy. In the U.S., pre-hospital triage is governed by each state. We aimed to understand hospital arrival times by state and race/ethnicity.

Methods
This cross-sectional observational study included adult patients with acute ischemic stroke treated at the Get With The Guidelines-Stroke (GWTG-Stroke) participating hospitals from January 2021 to August 2023. The primary outcome was the proportion of patients with onset-to-arrival (OTA)>4.5 hours. Multivariable logistic regression models were adjusted for patient- and hospital-level potential confounding factors.

Results
This study included 691,689 patients (66.2% White, 17.1% Black, 8.8% Hispanic, 3.4% Asian, and 4.4% other / undetermined), 49.8% with OTA >4.5 hours. OTA>4.5 hours occurred in 55% of Asian patients, 54% of Black patients, 52% of Hispanic patients, and 48% of White patients. Compared to White patients, Asian [adjusted odds ratio (aOR), 1.24; 95% CI 1.20-1.28], Black (aOR, 1.18; 95% CI 1.16-1.19), and Hispanic patients (aOR, 1.10; 95% CI 1.07-1.12) were more likely to present after 4.5 hours of stroke onset. The percentages of patients with OTA>4.5 hours in each race and ethnicity by state are depicted in the Figure. States with the highest percentages of OTA>4.5 hours were North Dakota for Asian patients (83%); and Vermont for Black (90%), Hispanic (100%), and White (55%) patients. After risk adjustment, compared to Texas which had the highest diversity index, states with the highest odds of OTA>4.5 hours in all patients were Vermont (1.31; 95% CI, 1.13-1.52), Mississippi (1.15; 95% CI, 1.04-1.28), North Carolina (1.15; 95% CI, 1.06-1.24) and Kentucky (1.15; 95% CI, 1.06-1.25). For the combined group of underrepresented Asian, Black, and Hispanic patients, the adjusted analysis showed that the highest odds of OTA>4.5 hours were in Vermont (5.68, 95% CI 4.30-7.51), District of Columbia (1.39, 95% CI 1.06-1.83), Utah (1.37, 95% CI 1.08-1.75) and Rhode Island (1.36, 95% CI 1.15-1.60) compared to Texas.

Conclusions
Asian, Black, and Hispanic patients are more likely to arrive after 4.5 hours of stroke onset than White patients, with a state-specific pattern. Further studies and interventions of these states and culturally tailored interventions are warranted to improve arrival times and time-dependent stroke treatment.
  • Chen, Bing Yu  ( Cleveland Clinic , Cleveland , Ohio , United States )
  • Xian, Ying  ( UTSW , Dallas , Texas , United States )
  • Uchino, Ken  ( CLEVELAND CLINIC FOUNDATION , Cleveland , Ohio , United States )
  • Man, Shumei  ( Neurological Institute, Cleveland C , Rocky River , Ohio , United States )
  • Sun, Jie-lena  ( Duke Clinical Research Institute , Raleigh , North Carolina , United States )
  • Fonarow, Gregg  ( UCLA MEDICAL CENTER , Los Angeles , California , United States )
  • Alhanti, Brooke  ( Duke University , Durham , North Carolina , United States )
  • Mac Grory, Brian  ( Duke Clinical Research Institute , Raleigh , North Carolina , United States )
  • Smith, Eric  ( UNIVERSITY OF CALGARY , Calgary , Alberta , Canada )
  • Schwamm, Lee  ( Yale School of Medicine , New Haven , Connecticut , United States )
  • Bhatt, Deepak  ( Mount Sinai Fuster Heart Hospital , Scarsdale , New York , United States )
  • Saver, Jeffrey  ( GEFFEN SCHOOL OF MEDICINE AT UCLA , Los Angeles , California , United States )
  • Author Disclosures:
    Bing Yu Chen: DO NOT have relevant financial relationships | Ying Xian: DO NOT have relevant financial relationships | Ken Uchino: DO have relevant financial relationships ; Consultant:Evaheart, Inc.:Active (exists now) | Shumei Man: DO NOT have relevant financial relationships | Jie-Lena Sun: DO NOT have relevant financial relationships | Gregg Fonarow: DO NOT have relevant financial relationships | Brooke Alhanti: DO NOT have relevant financial relationships | Brian Mac Grory: DO have relevant financial relationships ; Research Funding (PI or named investigator):National Institutes of Health:Active (exists now) ; Research Funding (PI or named investigator):American Heart Association:Active (exists now) | Eric Smith: DO NOT have relevant financial relationships | Lee Schwamm: DO have relevant financial relationships ; Consultant:genentech:Active (exists now) ; Advisor:Penumbra:Past (completed) ; Consultant:medtronic:Active (exists now) | Deepak Bhatt: DO have relevant financial relationships ; Advisor:Angiowave, Bayer, Boehringer Ingelheim, CellProthera, Cereno Scientific, Elsevier Practice Update Cardiology, High Enroll, Janssen, Level Ex, McKinsey, Medscape Cardiology, Merck, MyoKardia, NirvaMed, Novo Nordisk, PhaseBio, PLx Pharma, Stasys:Active (exists now) ; Other (please indicate in the box next to the company name):Honoraria cont: Journal of the American College of Cardiology (Guest Editor; Associate Editor), K2P (Co-Chair, interdisciplinary curriculum), Level Ex, Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Oakstone CME (Course Director, Comprehensive Review of Interventional Cardiology), Piper Sandler, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), WebMD (CME steering committees), Wiley (steering committee);:Active (exists now) ; Other (please indicate in the box next to the company name):Trustee: American College of Cardiology; Unfunded Research: FlowCo.:Active (exists now) ; Other (please indicate in the box next to the company name):Site Co-Investigator: Abbott, Biotronik, Boston Scientific, CSI, Endotronix, St. Jude Medical (now Abbott), Philips, SpectraWAVE, Svelte, Vascular Solutions;:Active (exists now) ; Royalties/Patent Beneficiary:Royalties: Elsevier (Editor, Braunwald’s Heart Disease);:Active (exists now) ; Research Funding (PI or named investigator):Abbott, Acesion Pharma, Afimmune, Aker Biomarine, Alnylam, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CinCor, Cleerly, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Merck, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Otsuka, Owkin, Pfizer, PhaseBio, PLx Pharma, Recardio, Regeneron, Reid Hoffman Foundation, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, Youngene, 89Bio;:Active (exists now) ; Royalties/Patent Beneficiary:Sotagliflozin (named on a patent for sotagliflozin assigned to Brigham and Women's Hospital who assigned to Lexicon; neither I nor Brigham and Women's Hospital receive any income from this patent);:Active (exists now) ; Other (please indicate in the box next to the company name):Other: Clinical Cardiology (Deputy Editor);:Active (exists now) ; Other (please indicate in the box next to the company name):American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org; Chair, ACC Accreditation Oversight Committee), Arnold and Porter law firm (work related to Sanofi/Bristol-Myers Squibb clopidogrel litigation), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Canadian Medical and Surgical Knowledge Translation Research Group (clinical trial steering committees), CSL Behring (AHA lecture), Cowen and Company, Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology),:Active (exists now) ; Other (please indicate in the box next to the company name):Data Monitoring Committees: Acesion Pharma, Assistance Publique-Hôpitaux de Paris, Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Boston Scientific (Chair, PEITHO trial), Cleveland Clinic, Contego Medical (Chair, PERFORMANCE 2), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo; for the ABILITY-DM trial, funded by Concept Medical; for ALLAY-HF, funded by Alleviant Medical), Novartis, Population Health Research Institute; Rutgers University (for the NIH-funded MINT Trial);:Active (exists now) ; Consultant:Broadview Ventures, GlaxoSmithKline, Hims, SFJ, Youngene:Active (exists now) ; Individual Stocks/Stock Options:Board of Directors: Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock):Active (exists now) ; Other (please indicate in the box next to the company name):Board of Directors: American Heart Association New York City, Angiowave (stock options), Bristol Myers Squibb (stock), DRS.LINQ (stock options), High Enroll (stock):Active (exists now) | Jeffrey Saver: DO have relevant financial relationships ; Consultant:Abbott:Active (exists now) ; Individual Stocks/Stock Options:Viz.ai:Active (exists now) ; Individual Stocks/Stock Options:Let's Get Proof:Active (exists now) ; Individual Stocks/Stock Options:Neuronics:Active (exists now) ; Consultant:Genentech:Expected (by end of conference) ; Consultant:Roche:Active (exists now) ; Consultant:Novo Nordisc:Active (exists now) ; Consultant:AstraZeneca:Active (exists now) ; Consultant:BrainQ:Active (exists now) ; Consultant:Medtronic:Active (exists now)
Meeting Info:
Session Info:

Health Services, Quality Improvement, and Patient-Centered Outcomes Posters I

Wednesday, 02/05/2025 , 07:00PM - 07:30PM

Poster Abstract Session

More abstracts on this topic:
Association of Sociodemographic Characteristics on Costs of Care in Patients with Obstructive Hypertrophic Cardiomyopathy

Reza Nosheen, Butzner Michael, Batra Kirti, Amos Qiana, Buikema Ami, Anderson Amy, Shreay Sanatan, Owens Anjali

Analysis of Racial Disparities in the Training Path to Cardiology: Trends from 2012 to 2022

Gopal Jay, Rahafrooz Maryam, Chan Nathan, Gopal Devraj, Kepler Joshua, Ren Junling, Gopal Indulekha, Joseph Jacob

More abstracts from these authors:
Elevated International Normalized Ratio Is Associated with Severity of Intracerebral Hemorrhage for Patients Taking Direct Oral Anticoagulants

Lusk Jay, Matsouaka Roland, Xian Ying, Sun Jie-lena, Mac Grory Brian, Schwamm Lee, Smith Eric, Fonarow Gregg, Bhatt Deepak, Saver Jeffrey, Reeves Mathew

Elevated International Normalized Ratio Is Inconsistently Associated With Ischemic Stroke Severity and Outcomes for Patients Taking Direct Oral Anticoagulants

Lusk Jay, Matsouaka Roland, Xian Ying, Sun Jie-lena, Mac Grory Brian, Schwamm Lee, Smith Eric, Fonarow Gregg, Bhatt Deepak, Saver Jeffrey, Reeves Mathew

You have to be authorized to contact abstract author. Please, Login
Not Available

Readers' Comments

We encourage you to enter the discussion by posting your comments and questions below.

Presenters will be notified of your post so that they can respond as appropriate.

This discussion platform is provided to foster engagement, and simulate conversation and knowledge sharing.

 

You have to be authorized to post a comment. Please, Login or Signup.


   Rate this abstract  (Maximum characters: 500)